SCHEMBL5367229

SCHEMBL5367229

CNS(=O)(=O)c1ccc2c(c1)C(=Cc1ccc(O)cc1O)C(=O)N2

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 4/20 0.55
SRC P12931 5/20 0.54
NTRK3 Q16288 3/20 0.54
NTRK2 Q16620 3/20 0.54
FCER2 P06734 2/20 0.54
SYK P43405 2/20 0.54
CDK2 P24941 2/20 0.52
KDR P35968 4/20 0.51
LCK P06239 2/20 0.48
FYN P06241 2/20 0.48
YES1 P07947 2/20 0.48
PDGFRB P09619 2/20 0.48
FGFR1 P11362 2/20 0.48
TYR P14679 2/20 0.47
AURKA O14965 1/20 0.47
PDPK1 O15530 4/20 0.46
APP P05067 1/20 0.46
MAPT P10636 1/20 0.46
SNCA P37840 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5369883 0.91 NTRK1 (0.55) NTRK1SRCNTRK3NTRK2FCER2
SCHEMBL5374277 0.89 SYK (0.68) NTRK1SRCNTRK3NTRK2FCER2
SCHEMBL7137047 0.89 SRC (0.52) NTRK1SRCNTRK3NTRK2FCER2
SCHEMBL5366048 0.87 SRC (0.57) NTRK1SRCNTRK3NTRK2FCER2
SCHEMBL5363355 0.87 SYK (0.58) NTRK1SRCNTRK3NTRK2FCER2
SCHEMBL5360933 0.87 MAP3K7 (0.58) NTRK1SRCNTRK3NTRK2FCER2
SCHEMBL5365190 0.85 PSEN1 (0.60) SRCCDK2KDRPDGFRBAPP
SCHEMBL5364692 0.85 SRC (0.52) NTRK1SRCNTRK3NTRK2FCER2
SCHEMBL5363476 0.85 SRC (0.51) NTRK1SRCNTRK3NTRK2FCER2
SCHEMBL7138011 0.84 SRC (0.50) NTRK1SRCNTRK3NTRK2FCER2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK NTRK1 223/4885SRC 189/4885NTRK3 358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.